We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

140 hedge funds and large institutions have $214M invested in PDL BioPharma, Inc. in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 59 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

306% more call options, than puts

Call options by funds: $191K | Put options by funds: $47K

5% less funds holding

Funds holding: 148 → 140 (-8)

32% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 22

35% less capital invested

Capital invested by funds: $332M → $214M (-$118M)

37% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 59

Holders
140
Holders Change
-8
Holders Change %
-5.41%
% of All Funds
3.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
37
Reduced
59
Closed
22
Calls
$191K
Puts
$47K
Net Calls
+$144K
Net Calls Change
-$174K

Top Buyers

Rank Fund Capital Flow
1
BIP
Brandes Investment Partners
California
+$3.46M
2
Morgan Stanley
Morgan Stanley
New York
+$3.2M
3
CM
Crestline Management
Texas
+$1.94M
4
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D
New Jersey
+$1.82M
5
JP Morgan Chase
JP Morgan Chase
New York
+$1.69M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$9.15M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$8.25M
3
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$3.81M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$2.23M
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$1.7M

PDLI Hedge Fund Activity: Q3 2019 in Review

140 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2019, worth a combined $214M — down 35% from $332M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of PDLI and 15 opened new positions — a net loss of 7 holders — while 59 trimmed existing stakes and 37 added.

The largest buyer was Brandes Investment Partners, adding an estimated $3.46M. The largest seller was State Street, cutting an estimated $9.15M.

  • 140 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2019, down from 148 in Q2 2019.
  • Funds reported $214M of PDL BioPharma, Inc. stock for Q3 2019, down 35% quarter-over-quarter.
  • 15 funds opened new PDL BioPharma, Inc. positions in Q3 2019 and 22 closed out, a net change of -7 holders.
  • The largest PDL BioPharma, Inc. buyer in Q3 2019 was Brandes Investment Partners, an estimated $3.46M added.
  • The largest PDL BioPharma, Inc. seller in Q3 2019 was State Street, an estimated $9.15M sold.

Based on aggregated 13F filings for Q3 2019.